Pyruvate dehydrogenase complex (PDC) is an important enzyme complex in the body that plays a key role in energy metabolism and the production of ATP. It is a large, multi-subunit enzyme complex that is found in the mitochondria of all eukaryotic cells. PDC is responsible for the conversion of pyruvate, the end product of glycolysis, into acetyl-CoA, which is then used in the citric acid cycle for the production of ATP. In this article, we will discuss the structure, function, and importance of the pyruvate dehydrogenase complex.
The pyruvate dehydrogenase complex is composed of three different enzymes: pyruvate dehydrogenase (E1), dihydrolipoamide dehydrogenase (E2), and dihydrolipoamide transacetylase (E3). The E1 enzyme is a homodimer composed of two identical subunits, each containing a single active site. The E2 enzyme is a homotetramer composed of four identical subunits, each with a single active site. The E3 enzyme is a homodecamer composed of ten identical subunits, each with a single active site. The three enzymes are held together by non-covalent interactions.
The pyruvate dehydrogenase complex is responsible for the conversion of pyruvate to acetyl-CoA. This reaction involves the oxidation of pyruvate and the reduction of NAD+. The reaction is catalyzed by the E1 enzyme, which is a pyruvate dehydrogenase. The E1 enzyme converts pyruvate to a hydroxyethyl-TPP intermediate, which is then converted to acetyl-CoA by the E2 and E3 enzymes. The E2 enzyme is a dihydrolipoamide dehydrogenase, which catalyzes the oxidation of the hydroxyethyl-TPP intermediate and the reduction of NAD+. The E3 enzyme is a dihydrolipoamide transacetylase, which catalyzes the transfer of the acetyl group from the hydroxyethyl-TPP intermediate to coenzyme A.
The activity of the pyruvate dehydrogenase complex is regulated by several different mechanisms. The activity of the E1 enzyme is regulated by covalent modification, in which the enzyme can be phosphorylated or dephosphorylated. The activity of the E2 enzyme is regulated by allosteric inhibition, in which the enzyme is inhibited by the binding of NADH. The activity of the E3 enzyme is regulated by covalent modification, in which the enzyme can be phosphorylated or dephosphorylated.
The pyruvate dehydrogenase complex is an important enzyme complex that plays a key role in energy metabolism and the production of ATP. The PDC is responsible for the conversion of pyruvate, the end product of glycolysis, into acetyl-CoA, which is then used in the citric acid cycle for the production of ATP. In addition, the PDC is also involved in the regulation of fatty acid oxidation and gluconeogenesis.
The pyruvate dehydrogenase complex is a large, multi-subunit enzyme complex that is found in the mitochondria of all eukaryotic cells. It is responsible for the conversion of pyruvate to acetyl-CoA, which is then used in the citric acid cycle for the production of ATP. The activity of the PDC is regulated by several different mechanisms, including covalent modification and allosteric inhibition. The PDC is an important enzyme complex that plays a key role in energy metabolism and the production of ATP.
1.
Next Day Mood Is Affected by Ability to Recover From Work.
2.
Enhanced CAR T cell therapy offers new strategy for lymphoma
3.
With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.
4.
Decrease seen in in situ breast cancer since 2009
5.
Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.
1.
Discovering the Benefits of TNK: A Comprehensive Blog Article
2.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
3.
Revolutionizing Cancer Treatment with Darzalex: How an Innovative Drug is Transforming Lives
4.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
5.
Precision Medicine and Genomics: Revolutionizing Healthcare Through Personalized Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
3.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
4.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
5.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation